Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01686958 · ClinicalTrials.gov registry record · NA
Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer
A NA study, sponsored by Profound Medical.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT01686958 is a NA study that has completed, run by Profound Medical. The registered enrollment target is 30 participants.
The verdict
NCT01686958, a NA study, has completed, sponsored by Profound Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.
Interventions
- DEVICE MR-Guided Transurethral US Ablation of Prostate Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-03-13 |
| Est. Completion | 2019-06-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01686958
The ClinicalTrials.gov registry entry for NCT01686958 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Profound Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MR-Guided Transurethral US Ablation of Prostate Tissue is the first listed.
NCT01686958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01686958 about?
NCT01686958 is a clinical study titled "Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer". This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.
What is the current status of trial NCT01686958?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2013-03-13. Estimated completion is 2019-06-11.
What interventions are being tested in trial NCT01686958?
The interventions under investigation include: MR-Guided Transurethral US Ablation of Prostate Tissue (DEVICE).
Who is sponsoring clinical trial NCT01686958?
This trial is sponsored by Profound Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.